Oxymorphone and oxycodone are not the same drug, though they are closely related. Both are semi-synthetic opioids derived from the same chemical family, and oxymorphone is actually one of the compounds your body produces when it breaks down oxycodone. That metabolic connection causes real confusion in clinical settings, from drug test interpretation to dosing when patients switch between the two. Despite their shared lineage, they differ in potency, how the body absorbs and processes them, how genetics influence their effects, and how they interact with other medications.
How the Two Drugs Are Related
Oxycodone and oxymorphone belong to the same class of opioid pain relievers and share a similar chemical backbone. The critical link between them is metabolic: when you take oxycodone, your liver converts a portion of it into oxymorphone through an enzyme called CYP2D6. This means oxymorphone is literally a breakdown product of oxycodone inside the body. That relationship matters for drug testing, because a person prescribed oxycodone alone can produce a positive result for oxymorphone on a urine screen, and this is expected rather than a sign of illicit use.
The fact that one drug is a metabolite of the other sometimes leads people to assume they are interchangeable or nearly identical. They are not. Oxymorphone was developed and approved as its own standalone medication, available in both immediate-release and extended-release oral forms as well as injectable formulations. The two drugs bind to the same primary target in the brain (the mu-opioid receptor), but they do so with different strengths, reach the brain by different pharmacological routes, and are processed by entirely different enzyme systems once you move past that initial metabolic step.
Potency Is Not the Same
One of the biggest practical differences is how much of each drug you need to achieve the same level of pain relief. In a head-to-head cancer pain trial, patients taking oxycodone controlled-release needed roughly twice the daily dose compared to those taking oxymorphone extended-release to get equivalent pain control, with mean daily doses of about 92 mg for oxycodone versus 46 mg for oxymorphone.1PubMed. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study That gives a roughly 2:1 oral dose ratio, meaning oxymorphone is about twice as potent milligram-for-milligram when taken by mouth.
The gap widens dramatically when the drugs are given intravenously. A pilot study comparing intravenous doses found oxymorphone to be roughly 12 to 14 times more potent than oxycodone on most measures.2PubMed Central. Relative potency of intravenous oxymorphone compared to other μ opioid agonists in humans – pilot study outcomes The reason for the discrepancy between oral and intravenous potency ratios comes down to absorption, which is covered below. The key takeaway for anyone switching between these medications is that the doses are absolutely not one-to-one, and mistaking one for the other at the same milligram amount could lead to a dangerous overdose or, conversely, inadequate pain control.
Why Oxymorphone Hits the Brain Faster Despite Poor Absorption
Here is where the pharmacology gets interesting. Oxymorphone is actually poorly absorbed when you take it by mouth. Only about 10% of an oral dose reaches the bloodstream, compared to roughly 50% for oxycodone and about 30% for morphine.3Essentials of Pain Medicine. Oxymorphone The liver chews up most of the oxymorphone before it ever gets a chance to circulate. That low bioavailability is why the oral potency ratio between the two drugs is “only” 2:1, even though oxymorphone binds far more tightly to opioid receptors.
At the receptor level, oxymorphone is in a different league. A ranking study that measured how tightly various opioids grip the mu receptor placed oxymorphone in the highest-affinity category, alongside hydromorphone and sufentanil, while oxycodone landed in the middle tier with morphine and fentanyl.4PubMed. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs That tighter binding, combined with oxymorphone’s greater fat solubility, means the drug that does make it into the bloodstream crosses into the brain more easily and gets to work quickly. The time to peak blood levels for immediate-release oxymorphone is about half an hour, compared to about an hour and a half for immediate-release oxycodone.3Essentials of Pain Medicine. Oxymorphone
So you end up with a paradox: the drug that is worse at surviving the trip through the gut still produces strong, fast-acting pain relief because what little gets through is extraordinarily good at reaching and activating opioid receptors in the brain. When the gut is bypassed entirely with an IV injection, that binding advantage shows up as the 12-to-14-fold potency difference mentioned earlier.
A Major Difference in How Each Drug Is Metabolized
This is arguably the most clinically significant distinction between the two, and it is one that many patients and even some prescribers underappreciate. Oxycodone relies heavily on the liver’s cytochrome P450 enzyme system for its metabolism, particularly CYP2D6 and CYP3A4. Oxymorphone, by contrast, does not go through the cytochrome P450 system at all.5PubMed Central. Concomitant Filled Prescriptions of Oxymorphone or Oxycodone with CYP3A Inhibitors and Inducers Instead, oxymorphone is broken down mainly through a process called glucuronidation, a different metabolic pathway.
This matters in two big ways. First, drug interactions. If you are taking oxycodone alongside another medication that blocks or speeds up CYP3A4 or CYP2D6, the amount of active oxycodone (and its metabolites) floating around your system can change unpredictably. Common CYP3A4 inhibitors include certain antifungals, some antibiotics, and even grapefruit juice. Oxymorphone sidesteps that entire category of interactions because it never touches those enzymes. For patients on complex medication regimens, that can be a meaningful advantage.
Second, genetics. The CYP2D6 enzyme that converts oxycodone into oxymorphone varies enormously from person to person based on inherited genetic differences. People fall along a spectrum from “poor metabolizers,” who barely convert any oxycodone to oxymorphone, to “ultra-rapid metabolizers,” who convert it very efficiently. In a study of postoperative patients, poor metabolizers needed more oxycodone to achieve the same pain relief compared to normal or ultra-rapid metabolizers.6PLOS ONE. CYP2D6 Genotype Dependent Oxycodone Metabolism in Postoperative Patients Separate research found that blocking CYP2D6 activity reduced oxycodone’s pain-relieving effect by about 30%, making the response look similar to a placebo.7PubMed Central. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety Ultra-rapid metabolizers, on the other hand, experienced heightened effects from the same dose.
Because oxymorphone’s breakdown does not depend on CYP2D6, this genetic variability is largely irrelevant when a patient is prescribed oxymorphone directly. For someone who is a CYP2D6 poor metabolizer and finds oxycodone ineffective, switching to oxymorphone could be a rational clinical move, since the active compound is delivered directly rather than relying on a sluggish enzyme to produce it.
Side Effects at Equal Doses
A systematic review comparing the two drugs found no significant differences in side effects between oxymorphone and oxycodone when they were given at equivalent pain-relieving doses.8Elsevier / ScienceDirect. A Systematic Review of Oxymorphone in the Management of Chronic Pain Both cause the standard opioid side effects you would expect: nausea, constipation, drowsiness, and dizziness. Neither drug appears to be clearly “gentler” than the other when the comparison is fair (that is, when doses are adjusted so both drugs are providing the same level of analgesia).
That said, individual experience varies. Some patients who struggle with nausea on one drug tolerate the other better, and vice versa. This is one reason clinicians sometimes rotate between opioids. Tolerance to the pain-relieving effects of one opioid does not always transfer fully to another, a phenomenon known as incomplete cross-tolerance.9Pain Medicine. Oxymorphone and Opioid Rotation So switching from oxycodone to oxymorphone (or the reverse) can sometimes restore some degree of pain control or reduce side effects, even after the first drug has become less effective over time. Clinicians typically reduce the calculated equivalent dose by a safety margin when rotating, precisely because cross-tolerance is unpredictable.
Drug Testing Complications
The metabolic relationship between these two drugs creates a specific headache for drug monitoring. Standard urine immunoassay screens for oxycodone are designed to cross-react with oxymorphone at concentrations of 100 nanograms per milliliter and above.10The Journal of Applied Laboratory Medicine. Challenges in Interpreting Unexpected Urine Drug Test Results This means a patient who is only prescribed oxycodone will often test positive for oxymorphone as well, because their liver naturally converts some oxycodone into oxymorphone and excretes it in urine.
The reverse can also cause confusion. If a patient is prescribed only oxymorphone and a screening test flags oxycodone, the clinician needs to consider whether a more specific confirmatory test (like mass spectrometry) is warranted before jumping to conclusions about unauthorized drug use. Unexpected results on urine drug screens are one of the most common sources of friction between pain management patients and their providers, and the oxycodone-oxymorphone metabolic overlap is a frequent culprit. If you are being monitored and see a result that looks wrong, this biochemistry is often the explanation, not noncompliance.
Abuse Potential and Regulatory History
Both drugs are Schedule II controlled substances in the United States, reflecting the government’s assessment that they carry a high risk of misuse and dependence. A human laboratory study comparing oral doses found that at moderate doses, oxymorphone appeared less potent than oxycodone on most measures related to euphoria and “liking.” However, at a higher dose of 40 mg, oxymorphone produced abuse-related subjective ratings similar to 40 mg of oxycodone.11PubMed Central. Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans The overall conclusion was that oxymorphone’s abuse liability is comparable to oxycodone’s, particularly at higher doses.
Oxymorphone’s regulatory history in the U.S. has been rockier. The FDA requested the removal of the original extended-release oxymorphone product (Opana ER) from the market in 2017, a highly unusual step, because of concerns that the reformulated version was being widely injected by people who crushed the tablets. The injection of those crushed tablets was linked to outbreaks of HIV and hepatitis C in certain communities. Oxycodone extended-release (OxyContin) had its own reformulation aimed at deterring crushing and snorting, and that product remains on the market. Generic extended-release oxymorphone products have since re-entered the market, but the episode illustrates how differently the two drugs’ abuse profiles played out in the real world, even when laboratory data suggest similar potential.
Kidney and Liver Disease
When a patient has impaired kidney or liver function, the choice between these drugs can matter more than usual. Both drugs need to be used cautiously in kidney disease, but the specifics differ. Oxycodone has been used in patients with kidney problems, generally with dose adjustments.12PubMed. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease Oxymorphone, being heavily processed through glucuronidation, produces metabolites that can accumulate when the kidneys are not clearing them efficiently, and its labeling recommends starting at lower doses in patients with moderate to severe kidney impairment.
Liver disease complicates things differently. Because oxymorphone already has such low oral bioavailability (that 10% figure), a damaged liver that processes less drug on the first pass can allow dramatically more oxymorphone into the bloodstream than expected. Oxymorphone’s labeling carries specific warnings about use in moderate to severe liver impairment. Oxycodone is also affected by liver disease, since it depends on hepatic CYP enzymes for metabolism, but its higher baseline bioavailability means the relative increase is less dramatic. Neither drug is “safe” in advanced liver disease, but the risk profiles are different enough that the choice between them may depend on a patient’s specific organ function.
Cost and Prescribing Patterns
In general practice, oxycodone is far more commonly prescribed and more widely available in generic form. One study comparing real-world consumption found that patients with low back pain used significantly more oxycodone controlled-release than oxymorphone extended-release over a 90-day period, a pattern that could have cost implications for healthcare systems.13PubMed Central. A Comparison of Daily Average Consumption Of Oxycodone Controlled Release (OxyContin CR) And Oxymorphone Extended Release (Opana ER) In Patients With Low Back Pain Because oxymorphone is roughly twice as potent orally, patients use fewer milligrams, but that does not necessarily translate to lower pharmacy costs since unit pricing differs.
Oxycodone’s broader availability means more generic options and generally more competitive pricing. Oxymorphone, while available in generic forms, has had a more turbulent market presence following the Opana ER withdrawal and its subsequent generic reintroductions. Some insurance formularies may prefer one over the other, and prior authorization requirements can vary. If your doctor is considering a switch between the two for financial reasons, the math is not as simple as comparing pill counts, since the dosing ratio, copay structure, and available strengths all factor in.
When Switching Between Them Makes Clinical Sense
Opioid rotation, the practice of switching a patient from one opioid to another, is a well-established clinical strategy. There are several scenarios where a switch between oxycodone and oxymorphone specifically might be warranted:
- Genetic poor metabolism: A patient on oxycodone who gets poor pain relief and is found to be a CYP2D6 poor metabolizer might respond better to oxymorphone, which does not rely on that enzyme.
- Drug interaction concerns: Someone starting a strong CYP3A4 inhibitor for another condition might be safer on oxymorphone, which avoids the CYP system entirely.
- Tolerance development: When a patient’s current opioid seems to be losing effectiveness, switching to a different one can exploit incomplete cross-tolerance to restore some analgesia at a lower equivalent dose.
- Side effect profile: Individual variation means some patients tolerate one drug better than the other, even at equivalent analgesic doses.
The conversion is not a simple calculation you should attempt on your own. Equianalgesic dose tables provide a starting point, but clinicians typically reduce the calculated dose by 25% to 50% when switching to account for incomplete cross-tolerance and individual variability. The standard oral conversion ratio of 2:1 (oxycodone to oxymorphone) is a population average from controlled trials and may not match your individual pharmacology.1PubMed. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study Close monitoring during the transition period is essential.
Food and Timing Considerations
One practical difference that catches patients off guard is how food affects each drug. Oxymorphone’s absorption can be significantly altered by eating, and its labeling typically instructs patients to take it on an empty stomach, at least an hour before or two hours after a meal. A high-fat meal can increase the amount of oxymorphone that reaches the bloodstream, which raises the risk of side effects or overdose if the dosing was calibrated for fasting conditions. Oxycodone, with its higher baseline bioavailability, is less dramatically affected by food, and its labeling does not carry the same strict fasting instructions. For patients who take pain medication around meals, this is not a trivial difference. Missing a meal or taking oxymorphone with breakfast without thinking about it can produce noticeably different effects from dose to dose, making pain control less predictable.